Gregory Fuller, MD
Family Medicine · Keller, TXNPI 1356347306
Payments from drug & device makers
Across 1,812 payments — averaging $6387.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5.5M
- Modernatx, Inc.$4.6M
- GSK$720K
- Janssen Research & Development, LLC$300K
- H. Lundbeck A S$151K
- Merck$78K
- plus $219K from 54 others
Across 1 payment — averaging $913.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$913
What the payments were for
- Consulting fees$6,31824%
- Travel & lodging$1,8527%
- Food & beverage$18,57869%
- Education$130%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$4,068
- S-217622$1,820
- NURTEC ODT$1,319
- PREVNAR - 13$1,214
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL)$421
- AIRSUPRA$381
- VRAYLAR$354
- QELBREE$334
- UBRELVY$330
- FARXIGA$275
- Vascepa$253
- VOQUEZNA$246
- TRELEGY ELLIPTA$245
- EMGALITY$244
- REYVOW$244
- RYBELSUS$239
- Otezla$235
- AIMOVIG$235
- BREZTRI$150
- Inspire$147
How this compares
$11,573,837 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $102,749 |
| JardianceEmpagliflozin | 65 | $77,385 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 39 | $44,552 |
| MounjaroTirzepatide | 39 | $42,870 |
| XareltoRivaroxaban | 29 | $31,289 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $26,228 |
| Xigduo XrDapaglifloz Propaned/Metformin | 29 | $24,386 |
| FarxigaDapagliflozin Propanediol | 18 | $23,047 |
| EliquisApixaban | 28 | $19,718 |
| Bydureon BciseExenatide Microspheres | 18 | $15,977 |
| MyrbetriqMirabegron | 12 | $14,422 |
| LinzessLinaclotide | 20 | $13,206 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 49 | $10,723 |
| VoqueznaVonoprazan Fumarate | 12 | $7,134 |
| QuviviqDaridorexant Hcl | 11 | $5,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $676 | $121,937104 claims |
| Novo NordiskOzempic | $1,332 | $102,74952 claims |
| Lilly USA, LLCMounjaro | $1,295 | $42,87039 claims |
| GSKTrelegy Ellipta, Shingrix | $719,637 | $36,95174 claims |
| Johnson & JohnsonXarelto | $221 | $31,28929 claims |
| AstraZenecaFarxiga, Symbicort | $18,009 | $25,76930 claims |
| PfizerEliquis, Paxlovid | $5,519,765 | $21,14742 claims |
| AbbVieLinzess, Synthroid | $1,554 | $17,72381 claims |
| Astellas Pharma US IncMyrbetriq | $248 | $14,42212 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $477 | $7,13412 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $326 | $5,38011 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $33 | $2,69311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Keller
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.